Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for those suffering with sickle cell disease. Ms Dasaolu, 31, has been admitted to ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle cell disease.

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The treatment uses gene-editing tool Crispr ... with joy as health officials approved a gene-editing therapy for certain children and adults with severe sickle cell disorder.

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

The US FDA announced ... for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA-cleared gene therapy to utilise the CRISPR ...